• While British Columbia is viewed as instrumental in Canada’s mining future, Torr Metals is developing its Kolos Copper-Gold Project located at the heart of British Columbia’s most significant copper mining district
• Torr recently expanded the project size by 75% to roughly 240 square kilometers
• Highlights of the strategic expansion includes several important new exploration findings that suggest Kolos may be a treasure trove of multiple potential discoveries, providing metals critical to the nation’s economy and security
• The company was also featured in a syndicated broadcast covering the increase in size of the project, establishing Torr Metals as a significant new player within the region

British Columbia is at the forefront of Canada’s push to become a major producer of 31 critical minerals. These minerals are essential for the future economy, and a recent expert panel highlighted the significant growth and job opportunities this presents for B.C.’s mining sector.

Torr Metals (TSX.V: TMET) intends to be part of this important economic growth and vital component to national security. The Vancouver-based company announced a major expansion of its Kolos Copper-Gold Project in B.C., part of the emerging Copper Highway, a region in the south-central portion of the province rich in mineral deposits, including five major copper mines at Mount Polley, Gibraltar, Highland Valley, Copper Mountain, and New Afton.

Through staking new mineral claims, Torr has increased the Kolos Project size by 75%, bringing the total area to approximately 240 square kilometers. Torr’s 100% owned project is located about 30 kilometers southeast of Canada’s largest open-pit copper mine at Highland Valley as well as 30 kilometers south of the New Afton Mine and 106 kilometers north of the Copper Mountain Mine; meaning all requisite mining infrastructure is located nearby. The Kolos Project is also just 23 kilometers north-northeast of the city of Merritt, British Columbia, providing low cost and year-round operation potential.

This strategic expansion focuses on the northern portion of the project and follows the trend of the Fanta Fault, a geological feature believed to be the main control on copper and gold mineralization in the area.

The key highlights of the expansion include:

• New Vik Zone Discovery. Torr identified a previously unknown mineralized rock outcrop in the eastern project area. A grab sample from this zone returned promising results, with 379 parts per million (“ppm”) copper (Cu) and 238 ppm molybdenum (Mo) that suggests proximity to the core of a potential copper porphyry system. This discovery sits near a high resistivity anomaly, a potential indicator of a mineralized intrusion, and is a high priority for Torr during upcoming exploration work.
• Highly Prospective Exploration Targets. The newly acquired claims cover several greenfield exploration areas in the north and east of the project that were delineated using Torr Metals established exploration model that has resulted in the previous discovery of 5 major mineralized zones. As such the following characteristics of these greenfield exploration targets hold tremendous promise:
  • Large-scale low magnetic geophysical anomalies: Two such anomalies share characteristics with the nearby Ram soil anomaly, which historically showed widespread Cu content (footprint of >200 ppm Cu measuring 900 meters by 500 meters)
  • Untested high resistivity geophysical anomalies: Similar to anomalies identified earlier this year, these newly discovered anomalies suggest potentially robust subsurface hydrothermal mineralization and alteration associated with outcrop mineralization at the Vik Zone
  • Unexplored magnetic signature: A large, unexplored circular magnetic low surrounded by magnetic highs is interpreted as a potential source of underexplored historical silver (Ag) anomalies apparent in regional silt stream sampling

All of these newly identified exploration targets are accessible by road via Highway 5 and other than a handful of regional silt stream samples have never been explored or drilled before. Torr has recently conducted reconnaissance field sampling over the past few weeks to further assess their potential.

“This expansion allows us to include highly prospective ground while focusing on our existing drill-ready zones,” said Malcolm Dorsey, President and CEO of Torr Metals. “The discovery of the Vik Zone demonstrates the effectiveness of our exploration strategy. We believe this expansion strengthens our long-term growth potential and positions us well for exciting new discoveries in the upcoming field season.”

Dorsey is justified in citing the potential for exciting porphyry discoveries. Not only is Teck’s Highland Valley Cu-Mo mine off to the west, but two other major Cu-Au deposits are in the region. To the north is New Afton, which Newgold shows to contain 34,087,000 @ 0.67 g/t Au, 1.69 g/t Ag, 0.73% Cu (Proven & Probable), 73,976,000 @0.57 g/t Au, 2.14 g/t Ag, 0.70% Cu (Measured & Indicated), 10,219,000 @0.33 g/t Au, 1.36 g/t Ag, 0.45% Cu (Inferred).

To the south is Copper Mountain, which is shown by Hudbay Minerals to host 367,000,000 tones of 0.12 g/t Au, 0.7 g/t Ag, 0.25% Cu (Proven and Probable), 138,000,000 tones @ 0.10 g/t Au, 0.7 g/t Ag, 0.21% Cu (Measured & Indicated), 371,000,000 tones @0.13 g/t Au, 0.6 g/t Ag, 0.25% Cu.

In addition, TMET announced that it has been featured in a broadcast via NetworkNewsAudio to discuss its 75% increase in the size of its BC copper-gold project. To hear the audio production, visit: https://ibn.fm/Xam1r

For more information, visit the company’s website at www.TorrMetals.com.

NOTE TO INVESTORS: The latest news and updates relating to TMET are available in the company’s newsroom at https://ibn.fm/TMET

The Future of Mining Perth invites resource industries, miners, innovators, and investors from across Australia, for two days of discussions, debates, learning, and collaborations on June 17-18, 2024 in Pan Pacific Perth. As the pressure of sustainable and efficient mining is growing, experts will share solutions and strategies to keep up with the technology revolution while still finding ways to maintain sustainable practices and do profitable business.

The event is expecting over 1,000 attendees comprising 700+ executives and decision-makers, 100+ industry leaders presiding over speaker sessions, and 60+ companies and brands looking to get insights and promote their brand in the resource and mining industry.

Some themes covered by the Future of Mining series:

• Technology Revolution
• Sustainability and ESG Practices
• Renewable Energy Integration
• Circular Economy and Recycling
• Community Engagement and Social Inclusion
• Responsible Mineral Supply Chains
• Regulatory and Policy Landscape
• Investing in Innovation

The event features two days of networking where mining and resource industry giant companies make their presence felt by sharing their thoughts on pivotal industry topics during speaker sessions, panel discussions, and more.

Newbies as well as veteran industries can market their brands and set up exhibitor booths to showcase their products and unique offerings. Discussions start right at the breakfast roundtables proceeding into a day full of energetic networking, bonding, and new business deals. Suppliers, mining companies, and investors can align on the same platform and discuss strategies of sustainable mining operations for energy transitions.

Startups and new companies trying to make an impact in the industry can leverage the connectivity and reach of the platform to showcase their brand in front of an impressive audience of industry leaders, mining companies, businesses, and investors. The Future of Mining event is organized by Aspermont Media, London, England.

To learn more, please visit https://ibn.fm/O502o.

Cultivators, manufacturers, entrepreneurs, traders, and enthusiasts, are invited to attend the Alternative Products Expo being held June 20-22, 2024, at the George R. Brown Center, in Houston. With its dynamic vibe of food, culture, art, and pulsating nightlife, Houston is the perfect venue for the Alternative Products Expo.

The Altpro Expo in Houston is hosted by USA CBD Expo, America’s leading CBD and Hemp Expo event organizers. Over recent years, they have expanded to include the full alternative products range ecosystem. Organized by ZJ Events, the Expo caters to the industry’s best CBD traders, manufacturers, and enthusiasts offering an exciting learning experience under a common arena.

With the Houston smoke shop scene in full swing, this year’s Expo is expected to showcase over 500 smoke shops, with numbers rising every year. Both emerging and seasoned brands benefit tremendously by exhibiting their products and services to the Expo’s crowd of enthusiastic audiences.

The Alternative Products Expo offers a phenomenal networking opportunity, where industry people can connect and collaborate with leading brand experts and manufacturers for long-term ROI. Attendees will discover the latest trends and novel ideas currently leading the industry. Exhibitors can showcase their unique offerings to grab a bigger share of the market. Traders can leverage the best show deals as fresh products are introduced with limited-time offers. Also, get updated on the latest regulations and learn the future course of the Alternative Products markets.

Trinity Hemp is the presenting sponsor of Alternative Products Expo Houston.

To learn more, please visit https://ibn.fm/fPr02

• Lexaria recently received two new patents granted in the U.S. in its patent families #21 and #24
• The new patents complement the company’s efforts in investigating the capabilities of DehydraTECH-CBD to lower blood pressure in humans with hypertension and mitigate epileptic seizures in rodents
• The company relies on R&D to provide data that enables it to apply for patent protection, supports further investigations and discoveries, as well as increases its chances of potentially receiving FDA approvals
• According to CEO Chris Bunka, the company’s growing patent portfolio forms the foundation upon which the company forges commercial relationships

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, started 2024 with a portfolio of 38 patents granted worldwide, having received ten new granted patents during 2023, the most yet in a single year. That patent portfolio, company CEO Chris Bunka explained in his 2024 letter to shareholders, provides vital support for Lexaria’s commercialization efforts as it forms “the foundation upon which future commercial relationships are built.” Yet, according to the letter, the company continues to expect additional patents to be awarded in the future and retains many valid patent applications throughout the world (https://ibn.fm/T8Hjo).

This year, the company has received five new patents, growing its portfolio to 43 granted patents worldwide. This follows the April receipt of three new patents and the most recent announcement of two important new patent awards captured in a May 2024 news release.

According to the announcement, Lexaria received a new granted patent in its patent family #21: Compositions and Methods for Treating Hypertension. This is the company’s third granted U.S. patent in this patent family. Lexaria also reported the receipt of a new granted patent in its patent family #24: Compositions and Methods for Treating Epilepsy. This is the company’s third granted U.S. patent in this patent family (https://ibn.fm/T59li).

The company’s growing list of granted patents results from early and ongoing R&D. According to Mr. Bunka, Lexaria uses study-dependent data from studies to confidently support its patent applications. But besides serving the “purpose of allowing us to more confidently apply for patent protection using the study-dependent data,” the studies provide data to potentially support further investigations and discoveries, as well as potential approvals by the U.S. Food and Drug Administration (“FDA”).

This approach, coupled with the long-term vision, has enabled the company to investigate the capabilities of various active pharmaceutical ingredients processed using its patented DehydraTECH(TM) drug delivery technology in human and animal studies. For instance, Lexaria has investigated the ability of DehydraTECH-processed cannabidiol (“CBD”) to potentially treat hypertension in humans and mitigate epileptic seizures in rodents. These applications are partly or wholly protected by the recently granted patents.

Lexaria has repeatedly demonstrated that DehydraTECH-CBD has shown an ability to lower blood pressure in both acute dosing in hypertension and over a 5-week study duration. In a series of four hypertension studies, the company evidenced DehydraTECH-CBD’s ability to lower human blood pressure (https://ibn.fm/HQ8Og), including in cases where the treatment was administered over an extended period (https://ibn.fm/FNrHg). The fourth study also led to the discovery of a potentially novel mechanism of action of DehydraTECH-CBD (https://ibn.fm/YvOE7).

These positive results encouraged the company to begin the process of seeking approval from the FDA to conduct a Phase 1b randomized, double-blind, placebo-controlled study of the safety, pharmacokinetics, and pharmacodynamics of DehydraTECH-CBD for the treatment of stage 1 or 2 hypertension. The company received earlier this year the FDA clearance to conduct the study (https://ibn.fm/5CK6B) and will provide updates on the status of this planned study in due course.

Beyond the treatment of hypertension, Lexaria has demonstrated, through an animal study, that DehydraTECH-CBD reduces or eliminates seizure activity in animals and, in some cases, even surpasses the performance of Epidiolex(R), one of the world’s leading anti-seizure medications. The company also reported that DehydraTECH-CBD suppresses body weight, improves triglyceride/cholesterol levels, and reduces blood glucose levels in an animal diabetes study.

The successes of these animal studies have supported the possibility of conducting additional human clinical studies of DehydraTECH-CBD. In addition to investigating DehydraTECH-CBD’s capabilities, Lexaria is also looking at the potential application of its drug delivery technology to GLP-1 drugs.

Supported by a robust growing portfolio of granted patents and encouraged by the positive results from its R&D activities, Lexaria continues to forge ahead, aiming to achieve its future business objectives.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Astrotech Corporation Subsidiary 1st Detect Approved as GSA Vendor; Introduces Advanced Narcotics Trace Detection Technology
• 1st Detect has now received approval from the U.S. General Services Administration (“GSA”) as an authorized vendor for government-related applications
• 1st Detect recently introduced a state-of-the-art Narcotics Trace Detection (“NTD”) narcotics library, which is particularly useful for detection at points of entry and government agencies involved in combating the illicit drug trade
• 1st Detect’s portfolio now includes the TRACER 1000, Explosives Trace Detection (“ETD”) and Narcotics Trace detection

Astrotech (NASDAQ: ASTC), through its subsidiary 1st Detect, is revolutionizing narcotics and explosives trace detection. With recent approval as a U.S. General Services Administration (“GSA”) authorized vendor, 1st Detect is poised to expand its impact across government agencies. TRACER 1000, a cutting-edge detector utilizing ruggedized mass spectrometry technology for superior detection at critical security points. 1st Detect’s commitment to excellence is underscored by its recent achievements and milestones, including its approval by the U.S. General Services Administration as an authorized vendor for key government-related applications (https://ibn.fm/EdwZq). This opens doors to 1st Detect’s products to a wide array of opportunities within government agencies tasked with ensuring national security.

At the heart of 1st Detect’s portfolio lies the TRACER 1000, a cutting-edge trace detector leveraging ruggedized mass spectrometry technology. This instrument represents the pinnacle of innovation in both ETD and now NTD, offering unmatched performance and versatility for security screening applications (https://ibn.fm/S1M7x).

Key features of the TRACER 1000:

• Ruggedized mass spectrometry technology
• Simple to use interface
• Seamless integration of new narcotics libraries

This development is particularly crucial for airport security and government agencies involved in combating the illicit drug trade by making updates for new drug profiles easy. By incorporating such advancements in mass spectrometry technology widely regarded as the “gold standard” in the industry, Astrotech has set a new standard for accuracy and reliability in narcotics detection.

Astrotech’s commitment to innovation and excellence was on full display at the recent ISC West Conference, held in April in Las Vegas. As a premier event focusing on security and public safety, ISC West provided an ideal platform for Astrotech to showcase its TRACER 1000 trace detector to industry professionals and decision-makers (https://ibn.fm/CHToD). The company’s participation underscores its dedication to staying at the forefront of technological advancements and addressing the evolving needs of the security market.

Thomas B. Pickens, III, Astrotech’s CEO, and Chief Technology Officer, said: “We are very excited about introducing our narcotics detection library that includes twelve illegal drugs including fentanyl, heroin, and cocaine.”  On the occasion, Pickens also said the company was extremely excited to share its user-friendly mass spectrometer the TRACER 1000 with leading industry experts and security industry professionals at the ISC West conference. “This allows us a platform to reach those in the industry across various markets, such as security, checkpoint, military, and law enforcement that strive for quality instrumentation, that requires a minimum amount of maintenance, and want accurate but rapid detection.”

For more information, visit the company’s website at www.AstrotechCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to ASTC are available in the company’s newsroom at https://ibn.fm/ASTC

• Nightfood is pioneering a new food product category: sleep-friendly nighttime snacks
• The Nightfood product line consists of sleep-friendly cookies in three flavors: Prime-Time Chocolate Chip, Snoozerdoodle and Date Night Cherry Oat, as well as ice cream in two flavors: Cookies N’ Dreams and Midnight Chocolate
• Nightfood, in February 2024, acquired Future Hospitality Ventures Holdings in an all-stock transaction
• Future Hospitality has secured valuable distribution agreements with industry-leading robotics manufacturers United Robotics Group and Botin Innovation
• Nightfood Holdings is acquiring additional synergistic companies to enhance its portfolio, drive value for shareholders and further its development plan

Nightfood Holdings (OTCQB: NGTF) is a visionary holding company focused on identifying and capitalizing on explosive market trends within hospitality, food services and consumer packaged goods. By leading newly emerging categories and seizing opportunities in markets undergoing transformational upheaval, the company’s mission is to create unparalleled upside potential in industries ripe for innovation and growth.

Subsidiaries

Nightfood Inc.

The company’s flagship subsidiary, Nightfood Inc., is changing the way the world snacks at night. Humans are biologically hard-wired to crave sweets and fats at night – a survival mechanism from our hunter-gatherer days. Modern consumers know bingeing excess calories before the long nightly fast is no longer necessary for survival, but exploding screen time and decreased willpower at night results in over 90% of American adults snacking between dinner and bed every week, contributing to an estimated one billion nighttime snack occasions weekly (according to SleepFoundation.org).

The most popular choices – ice cream, cookies, chips and candy – are not only unhealthy but also impair sleep quality due to their nutritional profiles. Nightfood snacks are uniquely formulated by sleep and nutrition experts to satisfy nighttime cravings AND support better sleep.

Market Opportunity

Euromonitor International projects the American snack market will grow from $150 billion in 2022 to $170 billion in 2027. Snacking between dinner and bed is estimated to account for over $60 billion annually, creating an opportunity for a multi-billion-dollar sub-category to emerge in the coming years: sleep-friendly snacking.

Nightfood is the brand pioneering that category.

Nightfood’s innovation has led to partnership overtures from global giants, including the largest food and beverage company in the world, Nestlé, with whom Nightfood completed a “test-and-learn” joint initiative in 2023.

Management believes that successfully scaling Nightfood’s 2024 direct-to-consumer launch of sleep-friendly cookies will bring the category to life, opening the door for partnerships with and potential acquisition by global snack giants seeking to lead this potential billion-dollar emerging sub-category.

Future Hospitality Ventures Holdings Inc. (d/b/a roboOp365)

Future Hospitality Ventures Holdings, operating under the brand roboOp365, is revolutionizing the hospitality industry with cutting-edge automation and robotic solutions.

roboOp365 enhances operational efficiency and guest experiences through innovative technologies, including automated culinary bot, server robots and AI-enhanced applications. roboOp365 helps hospitality providers reduce costs, streamline operations and deliver superior service by integrating these advancements.

Market Opportunity

The robots-as-a-service (“RaaS”) business model has gained significant traction, super-charged by the COVID-19 pandemic, which instantly catalyzed game-changing growth and application. According to Verified Market Research, the service robotics market is projected to reach $173.17 billion by 2030, growing at a compound annual growth rate (“CAGR”) of 21.25%. Compared to Asia, the United States market is in the early stages of adopting these technologies, but acceptance is accelerating aggressively.

Several factors are driving this trend. Key industries such as hotels and restaurants are still struggling to rebound from the pandemic’s impact, hoping to return to pre-pandemic levels, if possible. Such recovery will largely be dependent upon service robots. In California specifically, factors such as rising labor costs, more rigorous labor laws and ongoing high turnover rates in labor-intensive sectors make it impossible for businesses to survive, thrive and compete without robotics.

Innovation Across Sectors

Nightfood Holdings Inc. is dedicated to driving innovation across its focus sectors of food services, automation and hospitality applications. In food services, the company leverages automation technology to drive operational efficiency for operators while meeting evolving consumer needs. In the hospitality industry, it’s deploying solutions that redefine guest experiences. Nightfood’s consumer-packaged goods initiatives are key to breakthrough trends in health and wellness.

Synergizing Food and Technology

The synergy of food and technology within Nightfood Holdings Inc. creates a holistic approach to innovation and automation. By integrating these areas, the company offers comprehensive solutions that address multiple facets of market needs. Its automation and artificial intelligence solutions in food service and hospitality create a seamless and enhanced consumer experience.

Through this integrated approach, Nightfood Holdings Inc. not only meets current market demands but also anticipates and influences future trends, positioning itself as a leader in innovation across these interconnected sectors. Synergies in these related and explosive categories result in operational efficiency and benefits for the company’s customers and partners and outsized upside and opportunity for its investors.

Management Team

Sean Folkson is the Chairman and President of Nightfood. He founded Nightfood when he couldn’t find a solution to his nighttime snacking problem. Recognizing the growing body of research linking nutritional intake with sleep quality, he launched the first snack brand specifically formulated to give consumers better, healthier and more sleep-friendly snacks for that peak-cravings slot between dinner and bed. He is a serial entrepreneur and problem-solver, having previously founded Specialty Equipment Direct, an online distributor of floor removal equipment, and AffiliatePros.com, a pioneering company in online affiliate marketing.

Lei Sonny Wang is the CEO of Nightfood Holdings. He is a strategist and business driver for early-stage and growth-stage companies. He is the founder and former CEO of Future Hospitality Ventures Holdings Inc., which was acquired by Nightfood Holdings Inc. At Future Hospitality, he leveraged his significant international business development experience into distribution relationships with leading global robotics manufacturers. At Nightfood, he is working to grow revenue and improve performance and profitability across all subsidiaries.

For more information, visit the company’s website at https://ir.nightfood.com/. 

NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at http://ibn.fm/NGTF

• Tartisan Nickel Corp., a Canadian mineral and battery materials exploration and mining development company, recently announced a plan to complete an all-season access road at its flagship Kenbridge Nickel Project in Ontario
• This initiative will play a key role in improving the value of the property while also aligning with and providing benefit to Indigenous communities
• The move speaks to the company’s comprehensive and culturally sensitive approach to resource extraction, ultimately fostering a healthy relationship with the community

Tartisan Nickel (CSE: TN) (OTCQB: TTSRF) (FSE: 8TA), a Canadian mineral and battery materials exploration and mining development company, recently announced an ambitious plan to complete an all-season access road at its flagship Kenbridge Nickel Project in Ontario. As a critical initiative for the 2024 calendar year, its management noted its integral role in improving the property’s value, aligning with Indigenous communities.

“2024 promises to be a milestone year as multiple ongoing initiatives come together,” noted the company’s CEO, Mark Appleby. “Alignment with Indigenous communities, summation of baseline studies, project permitting endeavors, and all-season road access combined with continued efforts to expand the Kenbridge mine life are in focus and should prove to have a profound impact on shareholder value,” he added (https://ibn.fm/8EnR2).

To live up to its promise, Tartisan appointed Gregory (Greg) Edwards, B.Sc., Geo Eng., who would serve as Project Manager for the Kenbridge Nickel Project and the company’s First Nations Liaison. His appointment was informed by his consistent desire to work and foster good relationships with the three First Nations near the project. The move helped develop strong support from the surrounding indigenous community. To affirm that, in October 2021, the Kenbridge project received a blessing in a ceremony conducted by an elder from one of the First Nations, a tradition that it looks to maintain in all its projects going forward (https://ibn.fm/VqHNu).

Tartisan’s decisions and steps going forward are heavily informed by its surrounding community. As such, it looks to develop a more comprehensive and culturally sensitive approach to resource extraction by integrating traditional knowledge and leveraging Indigenous perspectives into their decision-making process. Adopting these steps, its management notes, will be integral in fostering a healthy and robust relationship with the community and extending the property’s life.

Its management maintains that 2024 will be a milestone year for the company. The additional claims acquisition earlier in May, its strategic appointments, and its partnerships so far in the year point to their confidence in the company’s direction and the potential of the flagship property. They also confirm its commitment to growing shareholder value while stamping Tartisan’s position as a leader in its space.

For more information, visit the company’s website at www.TartisanNickel.com.

NOTE TO INVESTORS: The latest news and updates relating to TTSRF are available in the company’s newsroom at https://ibn.fm/TTSRF

• Clene announced significant updates to their NIH-funded Accelerating Access to Critical Therapies Expanded Access Program (ACT-EAP) for CNM-Au8(R) compassionate use in amyotrophic lateral sclerosis (“ALS”)
• Clene has optimized its manufacturing, operational, and personnel processes to expand the program’s capacity to accommodate up to 180 participants
• The ACT-EAP, a collaboration among Clene, Columbia University, and Synapticure, was funded by the Accelerating Access to Critical Therapies for ALS Act (ACT for ALS), signed into law by Congress and President Biden in December 2021

Clene (NASDAQ: CLNN) and its subsidiary, Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company dedicated to improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases such as ALS and multiple sclerosis (“MS”), recently announced significant updates to their ACT-EAP for CNM-Au8 compassionate use in ALS (https://ibn.fm/aBWxl).

ALS is a fatal neurodegenerative disease with no known cure, making accessibility to treatment programs crucial. Recognizing this need, Clene has optimized its manufacturing, operational, and personnel processes to expand the program’s capacity to accommodate up to 180 participants.

In collaboration with Columbia University and Synapticure, Clene has secured a four-year grant totaling around $45m from the National Institute of Neurological Disorders and Stroke (“NINDS”), part of the NIH, to support an Expanded Access Program (“EAP”) for their investigational drug CNM-Au8 in ALS.

EAPs, also known as compassionate use programs, are FDA-regulated pathways that allow individuals with serious and life-threatening diseases to access investigational drugs not yet approved by the Food and Drug Administration. Funding for EAPs in ALS was strengthened by the ACT for ALS, signed into law by Congress and President Biden in December 2021.

Rob Etherington, CEO of Clene, said CNM-Au8 treatment has been associated with lowered risk of death and delayed clinical worsening, while being very well-tolerated in both of the company’s independent Phase 2 clinical studies. “Data from EAP programs, which usually include a broader ALS population than clinical trials, can supplement the safety and other meaningful data gathered from clinical studies,” Etherington added. “We are grateful for the NIH’s recognition to fund this important initiative and are pleased to provide this EAP for the ALS community. We are also grateful to the FDA for approving this EAP, working alongside Columbia University and Synapticure, to enable people who are living with this devastating disease access to our investigational drug CNM-Au8.”

Clene’s ACT-EAP is designed not only to meet FDA safety standards for EAPs but also to contribute valuable research data on ALS disease progression and therapy response. The program’s additional objectives include collecting real-world drug exposure data to enhance the CNM-Au8 clinical safety database and monitoring drug efficacy on survival and disease progression using natural history and control clinical trial database comparators. Biomarker data will also be collected and analyzed. This study is supported by the NIH under grant 1U01NS136023-01.

Dr. Jinsy A. Andrews, MD, MSc, FAAN, of Columbia University, and Principal Investigator on the grant, underscored that this was not just a standard EAP, in which Clene provides the investigational product to individuals with ALS through an FDA-regulated program. “A lot of time, careful thought, and effort have resulted in a study that will yield important insights into the real-world impact of CNM-Au8 treatment on the disease course of ALS,” Andrews explained.

The first patient visit for the ACT-EAP is scheduled for June 2024.

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

• CEO Dr. Alan Baratz recently published a piece for the Forbes Technology Council that highlighted the transformation potential in bringing these two technologies together
• D-Wave is helping companies explore the powerful combination of quantum computing with AI to drive innovation, reduce carbon emissions, and solve complex problems

As artificial intelligence (“AI”) continues its rapid enterprise adoption trend, there is growing interest in how quantum computing can be used in conjunction with AI to create better, more cost- and energy-effective solutions in various fields, such as material science, logistics, and complex optimization problems. The way the two technologies could be used together is explored in a Forbes Technology Council column by D-Wave Quantum (NYSE: QBTS) CEO Dr. Alan Baratz (https://ibn.fm/kBjT6).

D-Wave, a pioneer in quantum computing, is developing annealing quantum computing technology specifically designed to address these challenges. In the Forbes column, Baratz explains that as AI continues to evolve, so will the computational resources and energy needs required to train and develop AI models. According to Dr. Baratz, quantum computing can successfully address some of these challenges by “helping businesses get more out of AI without being constrained by the limitations of classical computing.” This could enhance the applications of both technologies, including chemical simulations for drug discovery and financial modeling.

To implement quantum AI into their operations, Dr. Baratz believes that enterprises should start incorporating quantum technologies as soon as possible in order to maximize the impact of AI and to engage internal teams to identify where quantum AI can support their specific business challenges.

Innovative organizations may view quantum computing as a strategic advantage to outpace competitors. Quantum technology could offer significant business value, including finding supply chain efficiencies, reducing waste, shortening time to solutions, and tackling complex problems previously deemed unsolvable. Data from Hyperion Research indicates that 80% of early adopters of quantum technology plan to increase their investment in the next two to three years, with one-third intending to invest at least $15 million USD in quantum initiatives (https://ibn.fm/eUCsK).

D-Wave has achieved technological milestones that could push the boundaries of what is possible with quantum computing. Its focus on creating scalable quantum solutions positions the company as a key player in the field, driving the adoption of quantum technologies in practical applications. As the convergence of AI and quantum computing reshapes the technological landscape, Dr. Baratz believes that businesses must prepare for the disruptive potential of these advancements.

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward-Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including the risks set forth under the heading “Risk Factors” discussed under the caption “Item 1A. Risk Factors” in Part I of the company’s most recent Annual Report on Form 10-K or any updates discussed under the caption “Item 1A. Risk Factors” in Part II of the company’s Quarterly Reports on Form 10-Q and in its other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to the company on the date hereof. The company undertakes no duty to update this information unless required by law.

The CWCBExpo is an essential B2B expo on the East Coast, being held at the Javits Convention Center in New York City. This year the Expo will be held from June 5-6, 2024, for two days of networking and engaging educational sessions.

The event schedule is meticulously planned as follows:

• June 4, 2024 – The exhibitors set up their booths, the pre-workshops are conducted on cultivation and operating a dispensary, and attendees can connect with industry colleagues at the rooftop bash that night.
• June 5, 2024 – After the registration and the media and press preview, the expo commences with a ribbon-cutting event. The expo floor opens and conference programs are conducted.
• June 6, 2024 – The attendees can participate in the conference programs and visit the expo on both the days. Along with business and networking, the participants can unwind, enjoy, and connect with industry influencers and peers at the luncheons, and after parties hosted by CWCBExpo on both the days.

Prominent members of the cannabis industry will share important insights, including:

• Industry icon Josh Kesselman, Founder and CEO, of HBI International / RAW Rolling Papers, who will preside over the fireside chat/keynote speaker session.
• Cy Scott, Co-Founder, CEO, of Headset, who will offer his insightful industry update on why New York is the next big cannabis market to watch out for and provide an update on rescheduling.

A special luncheon focusing on women in the cannabis business will be held on June 5, 2024. CWCBExpo is a leading B2B marketplace for networking within the cannabis community. Become a part of the interactive educational sessions, see unique product displays, participate in panel discussions, and seek the phenomenal opportunities offered by the CWCBExpo platform.

To learn more please visit https://ibn.fm/ZNIxm & https://ibn.fm/8lT47.